

## **PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy**

Sandip Pravin Patel and Razelle Kurzrock

**Center for Personalized Cancer Therapy, Division of Hematology and Oncology,**

UC San Diego Moores Cancer Center, San Diego, CA, USA

### **Corresponding Author Information:**

Sandip Pravin Patel

3855 Health Sciences Drive #0987

La Jolla, CA 92093-0987

Office: (858)-534-3804

Fax: (858)-246-0075

[sandippatel@ucsd.edu](mailto:sandippatel@ucsd.edu)

**Running header:** PD-L1 IHC as a predictive biomarker in cancer immunotherapy

**Acknowledgments:** Funded in part by the Joan and Irwin Jacobs Fund and MyAnswerToCancer philanthropic fund.

**Conflict of Interest:** SPP: None; RK: None.

**Study presented elsewhere:** No

## **Abstract**

The resurgence of cancer immunotherapy stems from an improved understanding of the tumor microenvironment. The PD-1/PD-L1 axis is of particular interest, in light of promising data demonstrating a restoration of host immunity against tumors, with the prospect of durable remissions. Indeed, remarkable clinical responses have been seen in several different malignancies including, but not limited to, melanoma as well as lung, renal and bladder cancer. Even so, determining which patients derive benefit from PD-1/PD-L1-directed immunotherapy remains an important clinical question, particularly in light of the autoimmune toxicity of these agents. The use of PD-L1 (B7-H1) immunohistochemistry (IHC) as a predictive biomarker is confounded by multiple unresolved issues: variable detection antibodies, differing IHC cutoffs, tissue preparation, processing variability, primary vs. metastatic biopsies, oncogenic vs. induced PD-L1 expression, and staining of tumor vs. immune cells. Emerging data suggest that patients with PD-L1 overexpression by IHC have improved clinical outcomes with anti-PD-1 directed therapy, but the presence of robust responses in some patients with low levels of expression of these markers complicates the issue of PD-L1 as an exclusionary predictive biomarker. An improved understanding of the host immune system and tumor microenvironment will better elucidate which patients derive benefit from these promising agents.

## Introduction

One of the initial observations of the important role that the host immune system plays in cancer control was made by Dr. William Coley at the turn of the century, when he described a patient with advanced sarcoma who achieved a complete remission (CR) following two severe bacterial skin infections (1). Over time, an improved understanding of immunobiology uncovered the importance of immune checkpoints in facilitating tumor escape, leading to the development of multiple novel therapeutics targeting the CTLA-4 (cytotoxic T-lymphocyte-associated protein 4, CD152) and PD-1/PD-L1 (programmed cell death protein 1, CD279; programmed death-ligand 1, CD274) immune checkpoints (2),(3),(4). In particular, melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC) have demonstrated durable responses to immune checkpoint inhibition (3),(4). For example, in patients with metastatic melanoma treated with concurrent ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1), 17% of patients achieved a CR, with an overall survival (OS) rate for all patients of 79% at two years (5). Thus, immunotherapy holds promise not only in attaining CRs in refractory patients, but in generating long-term remissions as well. With the recent regulatory approval of nivolumab (anti-PD-1, Bristol-Myers Squibb) and pembrolizumab (anti-PD-1, Merck) in the US, the search for a predictive biomarker to select for patients who would preferentially benefit from anti-PD-1/PD-L1 therapy becomes more pressing—both to spare patients ineffective therapy, and to limit the number of patients exposed to autoimmune side effects from agents targeting this axis (6).

Mitigation of autoimmunity via regulation of activated T cells is an important feature of immune homeostasis. T cell-antigen presenting cell (APC, dendritic cell or tumor cell) interactions and inhibitory checkpoints include (*format: receptor on T cell ~ ligands on antigen presenting cell*): CTLA-4~CD80/CD86, PD1~PD-L1/PD-L2,

GAL9~TIM3 (galectin-9/T cell immunoglobulin and mucin domain 3), TCR~LAG3 (T cell receptor/lymphocyte activation gene 3), and HVEM~BTLA (hepatitis virus entry mediator/B and T lymphocyte attenuator) (7). Overexpression of these inhibitory checkpoints by tumors, recruitment of immunosuppressive cells and factors into the microenvironment, and decreased immunogenic antigen presentation by tumor sculpt the immune microenvironment towards an immunosuppressive state via a process termed “immunoediting” (8). This tumorigenic process involves three phases: 1) an initial immune elimination of tumor followed by 2) an equilibrium state between the host immune system and tumor, and 3) generation of a tumor that evades immune surveillance through multiple immunoinhibitory mechanisms. Thus, immunoediting is a maladaptive reciprocal process by which the interaction between the host immune system and tumor results in the host immune system selecting for a less immunogenic tumor, and a tumor selecting for a less immunologically adept host.

PD-1 (CD279) is a T cell immune checkpoint involved in dampening autoimmunity in the peripheral effector phase of T-cell activation, leading to immune tolerance of cells expressing PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC) (9). PD-1, akin to its more centrally acting counterpart CTLA-4, is also preferentially expressed on regulatory T cells (Treg), an immune cell that contributes to the immunosuppressive tumor microenvironment, as well as on activated B cells and NK cells (9). PD-1/PD-L1 activation results in peripheral immunologic tolerance in T cells. In PD-1 and PD-L1 knockout mice, the autoimmune phenotype is milder as compared to that in CTLA-4 knockouts (10),(11). This parallels the clinical severity of observed toxicities of anti-PD-1/anti-PD-L1 and anti-CTLA-4 therapeutic monoclonal antibodies, which are more pronounced with the latter agent (12).

PD-L1 is expressed on a variety of cell types including placenta, vascular endothelium, pancreatic islet cells, muscle, hepatocytes, epithelium, and mesenchymal stem cells, as well as on B cells, T cells, dendritic cells, macrophages, and mast cells (13). PD-L2, a second ligand for PD-1, has a more restricted expression pattern, predominantly on dendritic cells, macrophages, and mast cells (14). Immune attack via interferon-gamma release leads to inducible upregulation of PD-L1 by mucosa creating an “immune shield” to protect against autoimmune attack in the setting of chronic inflammation or infection. Upregulated PD-L1 on these cells binds PD-1 on T cells, contributing to the development of T cell exhaustion (15). Tumor cells have coopted this PD-1/PD-L1 regulatory mechanism, designed to protect normal mucosa from autoimmune attack, and instead overexpress PD-L1 to avoid immunologic surveillance to facilitate cancer growth. We review here the early clinical experience and development of PD-L1 immunohistochemistry (IHC) as a predictive biomarker for anti-PD-1 directed therapy in human cancer.

### **PD-L1 Overexpression in Solid Tumors**

Multiple solid tumor types including melanoma, RCC, NSCLC, thymoma, ovarian, and colorectal cancer co-opt this immune shield by expressing PD-L1 to generate an immunosuppressive tumor microenvironment and avoid T cell cytotoxicity (16),(17),(18). Tumor PD-L1 overexpression confers a poorer prognosis across multiple tumor histologies, making therapeutic intervention on this immunomodulatory axis enticing (19),(20),(21),(22). With the success of targeting HER2-overexpressing cancers, utilizing IHC-based approaches to measure levels of HER2 expression, substantial effort has been expended on similar immunohistochemical approaches to screen tumors for PD-L1 expression in order to select for patients who may benefit from anti-

PD-1/PD-L1 directed therapies (23). However, to date, IHC-based detection of PD-L1 has been problematic in determining not only which tumor histologies are responsive to anti-PD-1/PD-L1 based immunotherapy, but also in determining which individual patients may benefit from therapy.

Tumor expression of PD-L1 in human cancer specimens is summarized by histology in **Table 1**. There is wide variability in the reported ranges of percent tumor samples overexpressing PD-L1 in a given histology, due to numerous factors that are discussed below. For the tumors classically associated with clinical responses to immune checkpoint inhibition with anti-PD-1 agents—melanoma, RCC, NSCLC, and, more recently, bladder cancer—the range of PD-L1 IHC expression on tumor ranges widely from 14% to 100%, highlighting the issues with PD-L1 as a predictive biomarker for this class of therapy (24),(25),(26). Among the hematologic malignancies, PD-L1 expression on FACS-separated malignant cells ranges from 37-58%, with higher expression in cancers driven by viruses such as EBV and HTLV (27). In comparison, tumor histologies currently thought to be less responsive to immune checkpoint inhibition, such as colorectal cancer and sarcoma, have tumor PD-L1 expression ranging in the 12%-53%, indicating that tumor PD-L1 IHC expression is not the sole determinant of which tumors histologies respond to PD-1/PD-L1 directed inhibition (28),(24).

### **Hematologic malignancies and PD-L1 expression**

Analysis of PD-L1 expression in hematologic malignancies as a predictive biomarker has also been studied. Flow cytometric measurement of PD-L1 expression has been utilized, and a general trend towards increased PD-L1 expression on virally-mediated hematologic cancers is apparent (27). Additionally, increased soluble PD-L1

(sPD-L1) in diffuse large B-cell lymphoma (DLBCL) is associated with inferior prognosis, particularly in patients with high-risk disease by International Prognostic Index (IPI), with 3-year OS of 40.9% in patients with elevated sPD-L1 and 82.1% in patients with non-elevated sPD-L1 ( $p < 0.01$ ) (29). However, analysis of PD-L1 expression as a predictive biomarker in hematologic malignancies has been limited to date, though a phase 2 study of pidilizumab (anti-PD-1) after autologous stem cell transplantation in DLBCL had a response rate of 51% in patients with measurable disease after transplant (30).

Classical Hodgkin lymphoma (HL), particularly the nodular sclerosis variant, has a unique mechanism of immune suppression and PD-L1/PD-L2 upregulation—via chromosome 9p24.1 amplification, which contains an amplicon containing PD-L1, PD-L1, and JAK2 (31). In a landmark phase 1 study of nivolumab in a highly refractory HL population (23 patients treated; 78% with prior autologous stem cell transplant, 78% with prior brentuximab vedotin treatment), 87% had an objective response including 17% with complete response (32). Exploratory biomarker analysis in 10 available biopsy specimens demonstrated 100% PD-L1 and PD-L2 expression on Reed-Sternberg cells by IHC, with PD-L1/PD-L2 copy number gain in 60% of samples, amplification in 40% of samples, and polysomy 9p in 80% of samples. Given these impressive results, there is intense clinical interest in immunomodulation for hematologic malignancies.

## **Tumor Molecular Phenotypes and PD-L1**

Within a given tumor histology, immune checkpoints may play a differential role based on tumor molecular phenotype. Within breast cancer, there is increasing recognition that the immune microenvironment has prognostic and predictive

implications for HER2-overexpressing and triple negative breast cancers (TNBC). Analyses of HER2-overexpressing breast cancer specimens from the GeparQuattro trial, a phase III neoadjuvant trial assessing different combinations of chemotherapy with trastuzumab, demonstrated improved pathologic complete response (pCR, 47.4% vs. 31.7%,  $p=NR$ ) in tumors with higher levels of tumor-infiltrating lymphocytes (TILs). A similar result was seen in the adjuvant FinHER trial, where a 10% increase in TILs was associated with a 16% increase in pCR ( $p=0.037$ ), and expression profiling of these samples demonstrated that trastuzumab was associated with improved outcomes in the setting of upregulated CTLA-4 and PD-1 expression (33). Experiments in a transgenic BALB/c-MMTV-neu mouse model demonstrated synergy between trastuzumab and anti-PD-1 and anti-PD-L1 antibodies (34). Based on an analysis of TNBC samples from the BIG 02-98 trial, a phase III adjuvant study comparing sequential versus concurrent docetaxel with anthracycline-based chemotherapy in breast cancer, a 10% increase in stromal TILs was associated with improved prognosis with a 15% reduction in relapse and a 17% reduction in death from TNBC (35),(36). Expression of PD-L1 by IHC appears to be increased in TNBC relative to that in hormone-driven tumors, and the prognostic importance of TILs in TNBC make the PD-1/PD-L1 axis appealing as a therapeutic target (37),(38). Recently, two phase 1 studies in metastatic TNBC have demonstrated preliminary signs of clinical activity. Among 27 patients treated with pembrolizumab, 1 patient had a complete response, 4 with a partial response, and 7 with stable disease (39). A similar study of 12 patients with TNBC treated with MPDL3280A resulted in 1 complete response, 2 partial responses, and 1 stabilization of disease (40). Further study is warranted, and an improved understanding of the unique biologic characteristics of the complete responders in the above study may help elucidate novel biomarkers.



In colorectal cancer, patients with microsatellite unstable (MSI-H) primary tumors have a superior prognosis, associated with increased TILs within tumor (41). In addition to increased TILs, MSI-H colorectal cancers have increased PD-L1 expression (56% vs. 21% in MSS tumors;  $p=0.007$ ), which may represent a unique molecular subset of patients with colorectal cancer that may benefit from PD-1/PD-L1 targeting therapy (42). One potential explanation for this series of findings is that MSI-H tumors, which are deficient in their ability to repair DNA mismatches, have an increased mutational burden resulting in increased neoantigen formation. These neoantigens are immunogenic, resulting in increased TILs in the MSI-H colorectal tumor microenvironment (43). Over time, an immunosuppressive tumor microenvironment is sculpted with overexpression of immune checkpoints such as PD-L1. Clinically, the potential benefit of immune checkpoint inhibition in MSI-H colorectal cancer is currently under active investigation (NCT02060188, NCT01876511; (44),(45)). Mutational burden appears to be correlated with response to immunotherapy between histologies as well. Tumor histologies with higher mutational burden--melanoma, NSCLC, and bladder cancer-- are also those histologies currently associated with superior responses to immune checkpoint blockade, including combinatorial strategies, relative to histologies with fewer mutations per megabase (46),(47). This may be due to a higher number of tumor mutations increasing the probability of generating a "high quality" immunogenic peptide, resulting in an improved anti-tumor response in the setting of checkpoint inhibitor therapy (48).

### Technical Issues with PD-L1 IHC

As summarized in **Table 1**, interpretation of PD-L1 by IHC in human tumor specimens is marred by multiple complicating factors. A multitude of detection PD-L1 IHC antibodies have been utilized including 28-8, 5H1, MIH1, and 405.9A11 (24),(38).

Additionally, a number of proprietary companion diagnostics are being developed in this area (**Table 2**). Comparative performance characteristics of these assays are not well known. The lack of a clear definition of “positive” tumor PD-L1 staining by IHC is problematic, with cutoff points for a positive result ranging from >1% to >50% based on percent tumor cells stained, compounding the existing issue of PD-L1 expression heterogeneity within the microenvironment (49),(50).

Furthermore, PD-L1 has limited binding sites for IHC detection antibodies, as it contains only two small hydrophilic regions, making immunohistochemical approaches classically used in formalin-fixed, paraffin-embedded (FFPE) specimens less effective (51),(52). Due to this lack of binding sites on PD-L1 amenable for IHC detection, IHC antibodies typically bind PD-L1 at structurally unique sites compared to therapeutic PD-L1 antibodies. Additionally, the use of multiple IHC cutoffs and proprietary PD-L1 IHC detection systems represents a barrier to interpretation of clinical trial biomarker data across trials. As summarized in **Table 3**, multiple agents have been studied with varying detection antibodies and IHC cutoffs, with the most data currently available in melanoma and NSCLC. The nivolumab phase 1 melanoma study compared a 1% versus 5% cutoff for PD-L1 status, by Dako (Carpinteria, CA) IHC, in archival tissue (53). For the 41 patient samples available for analysis, at the 1% cutoff, 26 were positive (35% response rate) and 15 were negative (13% response rate), while for the 5% cutoff 18 samples were positive (44% response rate) and 23 were negative (13% response rate). The response rate for the PD-L1 negative group remained unchanged (13%) when the 8 patients who were positive by the 1% cutoff were reclassified as negative by the 5% cutoff. The PD-L1 positive cohort had an improved response from 35% to 44% with an increase in the IHC cutoff, indicating the higher 5% IHC cutoff is reasonable in this analysis.

## Biological Issues with PD-L1 IHC

Mechanistically, PD-L1 is biologically active only when expressed on the cell membrane, either through dynamic interferon-gamma expression or through constitutive oncogene activation (9),(54). Oncogene-driven PD-L1 expression represents a histopathologically and biologically distinct entity compared to inflammation-driven PD-L1 expression. While the latter occurs focally at sites of interferon-gamma mediated immunologic attack, oncogene-driven PD-L1 expression is constitutive and diffuse (13). PD-L1 expressed during inflammation as a component of adaptive immune resistance is often associated with an immune infiltrate, while oncogene-driven PD-L1 expression is characterized by the lack of an immune infiltrate (54),(55). Numerous cell-signaling perturbations have been associated with constitutive PD-L1 expression across histologies. PTEN loss has been associated with upregulation of PD-L1 in glioblastoma multiforme (GBM) and colorectal cancer (56),(57). In GBM, Akt and Ras activation in combination with PTEN loss led to the highest levels of PD-L1 expression by IHC, with concomitant reduction in T cell killing *in vitro* (56). In colorectal cancer cell lines, PTEN knockdown by siRNA resulted in PD-L1 overexpression by IHC, independent of interferon-gamma stimulation (57). Notably, PD-L1 IHC staining in both studies was relatively diffuse within tumor, consistent with oncogene-dependent PD-L1 expression. Dysregulation in the JAK/STAT pathway can also result in oncogene-driven PD-L1 overexpression. STAT3 upregulation, via upstream activation of ALK, results in induction of PD-L1 and tumor evasion in T-cell lymphoma (58). PD-L1 upregulation in these experiments was independent of PI3K, mTor, or MEK/ERK signaling, demonstrating that multiple disparate signaling pathways are involved in PD-L1 regulation. In myeloma, both interferon-gamma as well as TLR signaling results in

upregulation of the STAT1, MyD88, and the MEK/ERK pathways (59). EGFR pathway activation in NSCLC also leads to PD-L1 upregulation, in addition to overexpression of a number of other immunosuppressive factors including IL-6 and TGF-beta (60). Inhibition of PD-1 in this EGFR-driven chimeric mouse model resulted in tumor regression and improved survival. Overall, an increasing number of signaling pathways are associated with PD-L1 regulation, lending support to the pursuit of combination therapies involving TKIs and immunotherapeutics.

In contrast to oncogene-mediated PD-L1 expression, interferon-gamma induced PD-L1 expression represents a dynamic biomarker and is present at sites of active inflammation, and biopsy samples represent a snapshot of the tumor immune microenvironment in space and time. Other factors in the tumor metabolic microenvironment, including hypoxia, can result in PD-L1 upregulation and are dependent on signaling via HIF-1 $\alpha$  (61). Smaller tumor biopsies may miss the pertinent tumor-immune interface, or the biopsy may be performed after the biologically relevant PD-L1 overexpression has already taken place. PD-L1 itself is expressed at two potentially clinically relevant immunologic synapses—the tumor/T-cell interface, as well as the antigen presenting cell (APC)/T cell interface (62). The majority of PD-L1 IHC biomarker development has been devoted to the former interface, but the latter likely plays a biologic role in tumor control as well, especially in light of the importance of the APC/T-cell interface for anti-CTLA-4 therapies (63). For the tumor/T-cell interface, biopsy capture of the tumor/immune interface is a key determinant in PD-L1 detection by IHC in melanoma. In a study assessing PD-L1 expression in patients with metastatic melanoma, 96% of PD-L1 overexpressing melanomas had a lymphocytic infiltrate, while the remaining 4% of PD-L1 overexpressing lacked TILs, possibly representing oncogene-driven PD-L1 expression (54). Additionally, 22% of PD-L1

negative samples were associated with a lymphocytic infiltrate, indicating alternative mechanisms of tumor immune interference. The majority of PD-L1 expression was at the tumor interface, with immune cells secreting interferon-gamma, leading to the counterintuitive hypothesis that PD-L1 overexpression may be an initially protective response to successful tumor killing by TILs, which over time becomes coopted into an immunosuppressive tumor environment. This parallels PD-1 biology, where PD-1 upregulation on T cells is initially associated with T cell activation; however over time PD-1 overexpression is a hallmark of T cell exhaustion, likely due to expression of other immune checkpoints such as LAG-3, TIM-3, and others (9). Thus, the prognostic and predictive impact of PD-L1 IHC is temporally dependent on the time of biopsy in relation to the development of the lesion as well as in relation to antecedent therapies, which may help reconcile findings that PD-L1 may be associated with improved prognosis in melanoma and cervical cancer, and poorer prognosis in other histologies such as RCC (64),(22). Additionally, the prognostic and predictive significance of PD-L1 expression on immune cells such as macrophages and lymphocytes may differ from tumor-associated PD-L1 expression in terms of the adaptive immune response (26). The role of anti-PD-1 and anti-PD-L1 directed therapies against oncogene-activated PD-L1 overexpressing tumors, in the absence of concomitant immune expression, will also require further study (65).

In addition to temporal considerations, numerous spatial considerations exist in terms of assessment of PD-L1 in cancer. Limited data exist comparing PD-L1 status in primary versus metastatic lesions, with few matched sets available from the same patient. As summarized in **Table 4**, there appears to be general parity between primary and metastatic lesions in terms of PD-L1 expression. However, amongst matched tumors in RCC, there was discordance in 5/33 samples, with 3 patients expressing PD-

L1 in the primary only, and 2 in the metastasis only (66). Data on clinical response to PD-1/PD-L1 directed therapies in these patients are not available, but utilizing PD-L1 as a negative biomarker to exclude patients from PD-1/PD-L1 directed immunotherapy is concerning given these discordant results. Additionally, selection of the appropriate site for biopsy for PD-L1 status remains enigmatic. While pre-treatment FFPE primary tumor samples may be most readily available, these samples may not reflect the overall immunologic landscape that currently exists in a given patient, particularly if interim treatment has been administered. The absence of PD-L1 expression in a biopsied lesion may not reflect the systemic immunologic landscape, and may not capture the beneficial effect therapy is having on other sites of disease that are dependent on PD-L1 signaling. This phenomenon is recognized in NSCLC with driver mutations, where the overall systemic burden of disease is being controlled by the TKI. Abrupt cessation of targeted therapy in this situation may result in a dramatic tumor flare and current management of focal progression is to continue the TKI to treat the concerning lesion with local measures (67). Alternatively, an enlarging lesion may represent a growing immune infiltrate invading a previously quiescent tumor, which may represent the biological basis for immune-related radiographic criteria in assessment of treatment response (68).

### **Clinical Experience with PD-L1 IHC**

A number of PD-1/PD-L1 targeting immunotherapeutics are under clinical development across multiple histologies, though predominantly in melanoma, RCC, and NSCLC to date (**Table 2**). Many of these trials have not reported or are utilizing a proprietary PD-L1 IHC companion diagnostic, limiting generalized analysis of biomarker data. Additionally, variation in IHC cutoff definitions complicates interpretation given the

lack of a working standard. Despite these issues, preliminary data suggests that patients with higher levels of PD-L1 expression by IHC have an improved response rate, PFS, and OS across histologies, as summarized in **Table 3**.

In melanoma clinical trials, PD-L1 overexpression by IHC is detected in approximately 45-75% of samples. In the nivolumab study, 45% of patients were positive for PD-L1 expression based on a 5% cutoff using the 28-8 detection antibody (53),(69). The response rate for PD-L1 positive patients was 44%, compared to 17% in PD-L1 negative patients. PD-L1 positive melanoma patients treated with nivolumab had an OS of 21.1 months and a PFS of 9.1 months, versus 12.5 months and 2 months in PD-L1 negative patients. Of note, while the general trend was a higher response rate with nivolumab in patients who were PD-L1 positive at a population level, on an individual level those PD-L1 negative patients that did respond to nivolumab (13%) had as robust a radiographic response as the elite PD-L1 positive responders, with a 75-100% reduction in measureable tumor. Pembrolizumab (anti-PD-1) has also been studied in advanced melanoma utilizing an IHC cutoff of 1% (70). PD-L1 positive patients (77%) had an ORR of 51%, while PD-L1 negative patients had an ORR of 6%. PD-L1 positive patients treated with pembrolizumab had a PFS of 12 months and a 1-year OS rate of 84%, while PD-L1 negative patients had a PFS of 3 months and a 1-year OS of 69%. Of note, approximately 20% of PD-L1 negative patients had a durable response to pembrolizumab by PFS, and OS data between groups were not statistically significant, with approximately 65% of patients in both groups with sustained responses. Similar data were seen in the phase 1 study evaluating nivolumab in combination with ipilimumab in melanoma, where a 5% PD-L1 IHC cutoff was used (5). While 57% of PD-L1 positive patients responded to combination immunotherapy, 41% of PD-L1 negative patients responded as well, with similar reductions in tumor size in responders

compared to PD-L1 positive responders. Conversely, patients that had disease progression on concurrent immunotherapy were those with PD-L1 negative tumors.

In NSCLC, a similar trend is seen as in melanoma, where PD-L1 positive patients seem to preferentially benefit from PD-1/PD-L1 directed therapy. Nivolumab was studied in patients with refractory NSCLC, and PD-L1 IHC was performed using a DAKO IHC assay with a 5% cutoff. Based on these criteria, 60% of patients were classified as positive for PD-L1, and the response rate in PD-L1-positive patients was 67% compared to 0% in PD-L1-negative patients (71). Pembrolizumab has also been investigated in NSCLC, utilizing a unique 50% IHC cutoff for PD-L1 expression with an unreported assay. Based on this cutoff, 25% of tumors were positive for PD-L1 and, at six months, PD-L1-positive patients had a 67% immune-related ORR (irORR), 67% PFS rate, and 89% OS rate compared to PD-L1-negative patients who had an 0% irORR, 11% PFS rate, and 33% OS rate (49). MPDL3280A, an anti-PD-L1 antibody, has also been studied in NSCLC utilizing a proprietary IHC platform with 0-3+ grading (3+ for >10% cells, 2+ for >5% cells, 0-1 for <5% cells) (72). NSCLC patients with 3+ PD-L1 expression had an 83% response rate, compared with 46% in patients with either 2+ or 3+ expression. Patients with 1+/2+/3+ PD-L1 expression had a 31% ORR. Based on this limited data, it appears patients with NSCLC with higher levels of PD-L1 by IHC have superior responses to PD-1/PD-L1 directed therapy, but less is known about the nature of responses or survival outcomes in PD-L1 negative patients treated with immunotherapy. On initial evaluation, it appears as if select PD-L1 negative patients with melanoma can still obtain durable responses to anti-PD-1/PD-L1 therapy, while response rates in NSCLC in PD-L1 negative patients are rare. Whether this trend is reproduced in larger trials in these histologies remains to be seen and, if so, may represent a fundamental difference in the immunobiology between tumor types that can



be exploited with novel immunotherapeutics, or a technical issue with IHC in different tissue types. For example in a phase 1 clinical trial of MPDL3280A in metastatic urothelial bladder cancer, PD-L1-positive patients had a 52% ORR at 12 weeks, compared to 11% in PD-L1-negative patients (25). The depth and duration of responses in PD-L1 negative patients remains to be seen.

PD-L1 IHC as a predictive biomarker has also been assessed in clinical trials involving multiple histologies. The nivolumab phase 1 study included patients with melanoma, RCC, NSCLC, mCRC, and mCRPC (4). PD-L1 was detected by 5H1 antibody utilizing a 5% threshold, and 60% of tumors were positive by this criterion. Patients with PD-L1 positive tumors had a 36% response rate, while patients with PD-L1 negative tumors had a 0% ORR. MPDL3280A has been studied in patients with melanoma, RCC, NSCLC, mCRC, and gastric cancer utilizing a proprietary PD-L1 IHC platform (73). PD-L1 positive patients had a 39% response rate, while PD-L1 negative patients had a 13% response rate.

## Conclusions

Immunotherapy represents a paradigm shift in oncology therapy along multiple fronts. While targeted therapy ameliorates the underlying signaling defect resulting in oncogenesis within the tumor, immune checkpoint blockade is fundamentally a therapy directed at the patient's native immune system to tilt immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing anti-tumor immunity. Based on the paradigm of matched therapy, it is not surprising that HER2 IHC is predictive of response to HER2 targeting therapy, or that inhibition of overexpressed BCR-ABL with small molecule inhibitors results in dramatic tumor responses—the underlying oncogenic defect is being detected and targeted by specific therapy (23),(74). With

immune checkpoint blockade of CTLA-4, PD-1, and PD-L1, the primary target is the host immune system, not the underlying intra-tumoral signaling defect. PD-L1 overexpression is not the oncogenic driver of the tumor, but rather a co-opted and maladaptive immune shield that protects the tumor from its immune microenvironment.

Patients who have PD-L1 overexpression, based on different assays with varying cutoffs, tend to have more robust responses to anti-PD-L1 directed therapy. For instance, patients with PD-L1 overexpressing melanoma have a 44-51% response rate to anti-PD-1-directed therapy, while patients with PD-L1 overexpressing NSCLC have a 67-100% response rate (**Table 3**). In contrast, patients with PD-L1-negative melanoma have response rates of about 6-17% (with some of these responses being durable); while for PD-L1-negative NSCLC, the response rate is about 0-15%. Therefore, PD-L1 IHC at present is not a clear-cut exclusionary predictive biomarker. This may not be surprising since few biomarkers represent binary variables. For instance, patients with a biomarker may not respond to a therapy because secondary biologic or molecular changes have occurred and drive the tumor. Similarly, patients negative for a biomarker may respond because activated biologic pathways may intersect and hence activate a pathway or signal, without the specific biomarker being activated or overexpressed. Technical factors and cut-off standards may also influence the utility of a biomarker. For example, even HER2, a *bona fide* oncologic driver with clear guidelines for HER2-directed therapy utilizing IHC and FISH assays, required a recent change in classification to lower the threshold for HER2 positivity (75). Overall, few biomarkers represent true dichotomous variables, with the utility of most being due to a statistically significant and clinically meaningful increase in response rate in patients harboring the biomarker.

Clinical responses to PD-1/PD-L1-directed therapy in refractory tumors such as melanoma, RCC, NSCLC are impressive and appear durable, similar to experience with other immunotherapeutics. The recent approval of nivolumab and pembrolizumab for ipilimumab-refractory metastatic melanoma in the US likely represent the first of many future indications for anti-PD-1 directed therapy. The continued development of PD-L1 IHC, along with other immunologic assays, as a predictive biomarker for anti-PD-1/anti-PD-L1 therapy is an important endeavor to potentially spare patients from ineffective therapy with autoimmune toxicity. Ultimately, immunotherapy, and immune checkpoint inhibition in particular, has led to a paradigm shift in oncology, requiring development of new radiographic response criteria and altering expectations for durable responses with therapy. The promising efficacy of these agents combined with an increasing understanding of the complicated interactions between the immune system and tumor foster optimism for progress in biomarker development in this field.

## Bibliography

1. Parish CR. Cancer immunotherapy: The past, the present and the future. *Immunol Cell Biol.* 2003;81:106–13.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med.* 2010;363:711–23.
3. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. *N Engl J Med.* 2012;366:2455–65.
4. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. *N Engl J Med.* 2012;366:2443–54.
5. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med.* 2013;369:122–33.
6. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma. *N Engl J Med.* 2013;369:134–44.
7. Patel SP, Osada T, Osada K, Hurwitz H, Lysterly HK, Morse MA. Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. *Curr Colorectal Cancer Rep.* 2013;9:391–7.
8. Dunn GP, Old LJ, Schreiber RD. The Three Es of Cancer Immunoediting. *Annu Rev Immunol.* 2004;22:329–60.
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer.* 2012;12:252–64.
10. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. *Annu Rev Immunol.* 2001;19:565–94.
11. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. *J Exp Med.* 2009;206:3015–29.
12. Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. *Br J Cancer.* 2013;108:1560–5.
13. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. *Nat Immunol.* 2007;8:239–45.

14. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. *Nat Immunol.* 2001;2:261–8.
15. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature.* 2006;439:682–7
16. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. *Cancer Immunol Immunother.* 2007;56:739–45.
17. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. *Proc Natl Acad Sci U S A.* 2002;99:12293–7.
18. Blank C, Gajewski T, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. *Cancer Immunol Immunother.* 2005;54:307–14.
19. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. *Cancer.* 2010;116:1757–66.
20. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. *Proc Natl Acad Sci.* 2007;104:3360–5.
21. Mu C-Y, Huang J-A, Chen Y, Chen C, Zhang X-G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. *Med Oncol.* 2011;28:682–8.
22. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up. *Cancer Res.* 2006;66:3381–5.
23. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. *N Engl J Med.* 2001;344:783–92.
24. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med.* 2002;8:793–800.
25. Powles T, Eder JP, Fine GD, Braiteh FS, Loria Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. *Nature.* 2014;515:558–62.

26. Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature*. 2014;515:563–7.
27. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML, et al. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. *Clin Cancer Res*. 2013;19:3462–73.
28. D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin L-X, Carvajal RD, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. *Hum Pathol*; Available from: [http://www.humanpathol.com/article/S0046-8177\(14\)00457-2/abstract](http://www.humanpathol.com/article/S0046-8177(14)00457-2/abstract)
29. Rossille D, Gressier M, Damotte D, Maucourt-Boulch D, Pangault C, Semana G, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. *Leukemia*. 2014;28:2367–75.
30. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen Y-B, et al. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. *J Clin Oncol*. 2013;31:4199–206.
31. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood*. 2010;116:3268–77.
32. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. *N Engl J Med* 2014;372:311–9.
33. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol*. 2014;25:1544–50.
34. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). *Cancer Res*. 2013;73:S1–05. Available from: [http://cancerres.aacrjournals.org/content/73/24\\_Supplement/S1-05.abstract](http://cancerres.aacrjournals.org/content/73/24_Supplement/S1-05.abstract)
35. Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, et al. Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02–98 Randomized Trial. *J Natl Cancer Inst*. 2008;100:121–33.
36. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the

Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. *J Clin Oncol*. 2013;31:860–7.

37. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et al. Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type. *Cancer Epidemiol Biomarkers Prev*. 2014;23:2965–70.
38. Grosso J, Inzunza D, Wu Q, Simon J, Singh P, Zhang X, et al. Programmed death-ligand 1 (PD-L1) expression in various tumor types. *J Immunother Cancer*. 2013;1:P53.
39. Nanda R, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart M, Emancipator K, Gonzalez EJ, Houp J, Pathiraja K, Karantza V, Iannone R, Gause CK, Cheng JD, Buisseret L. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. *San Antonio Breast Cancer Symposium 2014*; S1–09.
40. Emens LA BF, Cassier P, DeLord J-P, Eder JP, Shen X, Xiao Y, Wang Y, Hegde PS, Chen DS, Krop I. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. *San Antonio Breast Cancer Symposium 2014*; PD1–6.
41. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. *Cancer*. 2001;91:2417–22.
42. Gatalica Z, Snyder CL, Yeatts K, Xiao N, Holterman D, Lynch HT. Programmed death 1 (PD-1) lymphocytes and ligand (PD-L1) in colorectal cancer and their relationship to microsatellite instability status. *ASCO 2014*; *J Clin Oncol* 32:5s, 2014 (suppl; abstr 3625).
43. Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboue R, Laurent M, et al. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. *Mod Pathol*. 2009;22:1186–95.
44. A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142). Report No.: NCT02060188. Available from: <https://clinicaltrials.gov/ct2/show/NCT02060188?term=NCT02060188>
45. Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors. Report No.: NCT01876511. Available from: <https://clinicaltrials.gov/ct2/show/NCT01876511?term=NCT01876511>
46. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. *Nature*. 2013;500:415–21.



47. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. *J Clin Oncol*. 2015; Available from: <http://jco.ascopubs.org/content/early/2015/01/20/JCO.2014.59.4358.abstract>
48. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. *N Engl J Med*. 2014;371:2189–99.
49. Gandhi L, Balmanoukian A, Hui R, Hamid O, Rizvi NA, Leighl N, et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC). *AACR* 2014; CT105.
50. Marti AM, Martinez P, Navarro A, Cedres S, Murtra-Garrell N, Salva F. Concordance of PD-L1 expression by different immunohistochemistry (IHC) definitions and in situ hybridization (ISH) in squamous cell carcinoma (SCC) of the lung. *ASCO* 2014; *J Clin Oncol* 32:5s, 2014 (suppl; abstr 7569).
51. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nat Med*. 1999;5:1365–9.
52. Sznol M, Chen L. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. *Clin Cancer Res*. 2013;19:1021–34.
53. Hodi FS, Sznol M, Kluger HM, McDermott DF, Carvajal RD, Lawrence DP, et al. Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. *ASCO* 2014; *J Clin Oncol* 32:5s, 2014 (suppl; abstr 9002).
54. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. *Sci Transl Med*. 2012;4:127ra37.
55. Taube JM, Klein AP, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. *Clin Cancer Res*. 2014;3271.2013.
56. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. *Nat Med*. 2007;13:84–8.
57. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. *PloS One*. 2013;8:e65821.
58. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). *Proc Natl Acad Sci*. 2008;105:20852–7.



59. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN- $\gamma$  and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. *Blood*. 2007;110:296–304.
60. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. *Cancer Discov*. 2013;3:1355–63.
61. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells. *Cancer Res*. 2014;74:665–74.
62. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. *Proc Natl Acad Sci USA*. 2004;101:10691–6.
63. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. *J Exp Med*. 1995;182:459–65. Available from:
64. Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, et al. Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma. *Clin Cancer Res*. 2009;15:6341–7.
65. Ribas A, Tumei PC. The future of cancer therapy: Selecting patients who respond to PD-1/L1 blockade. *Clin Cancer Res*. 2014;0933.2014.
66. Callea M, Genega EM, Gupta M, Cheng S, Fay AP, Song J, et al. PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. *ASCO 2014; J Clin Oncol 32:5s*, 2014 (suppl; abstr 4585).
67. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn Jr PA, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene addicted non-small cell lung cancer. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer*. 2012;7:1807.
68. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. *Clin Cancer Res*. 2009;15:7412–20.
69. Postow M, Cardona D, Taube J, Anders R, Taylor C, Wolchok J, et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. *J Transl Med*. 2014;12:O8.
70. Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. *ASCO 2014; J Clin Oncol 32:5s*, 2014 (suppl; abstr 3005^).

71. Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Man LQ, Juergens RA, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. ASCO 2014 Poster J Clin Oncol 32:5s, 2014 (suppl; abstr 8024).
72. Soria JC, Cruz C, Bahleda R, Delord JP, Horn L, Herbst RS, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): Additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PD-L1). ECC 2013; Abstract 3408.
73. Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria J-C, Hamid O, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. ASCO 2014; J Clin Oncol 31, 2013 (suppl; abstr 3000).
74. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.
75. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31:3997–4013.
76. Grosso J, Horak CE, Inzunza D, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). ASCO 2013; Chicago IL; J Clin Oncol 31, 2013 (suppl; abstr 3016).
77. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005;104:2084–91.
78. Callea M, Gray KP, Ho TH, et al. PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors. ASCO 2014; J Clin Oncol 32:5s, 2014 (suppl; abstr 4526).
79. Figueroa DJ, Liu Y, Gagnon RC, et al. Correlation of PDL1 tumor expression and outcomes in renal cell carcinoma (RCC) patients (pts) treated with pazopanib (paz). ASCO 2014; J Clin Oncol 31, 2013 (suppl; abstr 3021).
80. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression. Clin Cancer Res. 2004;10:5094–100.
81. Sun J-M, Zhou W, Choi Y-L, et al. PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea. ASCO 2014; J Clin Oncol 32:5s, 2014 (suppl; abstr 8066).

82. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata. *Cancer*. 2007;109:1499–505.
83. Mullane SA, Werner L, Callea M, et al. PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma. ASCO 2014; J Clin Oncol 32:5s, 2014 (suppl; abstr 4552).
84. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 Blockade Augments Adoptive T-Cell Immunotherapy for Squamous Cell Carcinoma. *Cancer Res*. 2003;63:6501–5.
85. Berghoff AS, Kiesel B, Widhalm G, et al. PD1 and PD-L1 expression in glioblastoma. ASCO 2014; J Clin Oncol 32:5s, 2014 (suppl; abstr 2011).
86. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. *Neoplasia*. 2006;8:190.
87. Wu C, Zhu Y, Jiang J, Zhao J, Zhang X-G, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. *Acta Histochem*. 2006;108:19–24.
88. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer. *Clin Cancer Res*. 2005;11:2947–53.
89. Gao Q, Wang X-Y, Qiu S-J, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma. *Clin Cancer Res*. 2009;15:971–9.
90. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. *Clin Cancer Res*. 2007;13:2151–7.
91. Brown JA, Dorfman DM, Ma F-R, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. *J Immunol*. 2003;170:1257–66.
92. Padda SK, Riess J, Schwartz EJ, et al. Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA). ASCO 2014; J Clin Oncol 32:5s, 2014 (suppl; abstr 7606).
93. Chen X, Liu S, Wang L, Zhang W, Ji Y, Ma X. Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. *Cancer Biol Ther*. 2008;7:622–7.
94. Salih HR, Wintterle S, Krusch M, Kroner A, Huang Y-H, Chen L, et al. The role of leukemia-derived B7-H1 (PD-L1) in tumor–T-cell interactions in humans. *Exp Hematol*. 2006;34:888–94.

95. Tessari A, Paolini B, Mariani L, et al: Expression of PD-L1 and NY-ESO-1 in early and advanced triple-negative breast cancer. ASCO 2014; J Clin Oncol 32:5s, 2014 (suppl; abstr 1110).

**Table 1**  
**Prevalence of PD-L1 expression in human cancers**

Tumor Histology	Percent tumor samples expressing PD-L1	Tumor surface expression cutoff for positivity	PD-L1 detection antibody	Ref(s)
<b>Melanoma</b>	45%	5%	28-8	(76)
	100%	>10%	5H1	(24)
	91%	NR	R&D B7-H1	(37)
	38%	5%	5H1	(54)
	77%	1%	NR	(70)
<b>Renal Cell Carcinoma</b>	44% (primary tumor), 54% (metastasis)	10%	5H1	(77)
	24%	5%	5H1	(22)
	14%	5%	405.9A11	(78)
	24%	H-score >0	5H1	(79)
<b>Non-small cell lung cancer</b>	49%	5%	28-8	(76)
	52%	NR	R&D B7-H1	(37)
	95%	>10%	5H1	(24)
	50%	11%	MIH1	(80)
	21% (squamous only)	>1% vs. >5% vs. H-score	5H1	(50)
	60%	5%	DAKO IHC	(71)
	50%	1%	NR	(81)
<b>Bladder</b>	21% (37% squamous, 22% transitional)	5%	28-8	(38)
	28%	1%	5H1	(82)
	20%	5%	405.9A11	(83)
<b>Head and Neck</b>	31%	5%	28-8	(38)
	66%	10%	5H1	(84)
<b>Cervical</b>	29%	5%	28-8	(38)
	19%	NR	5H1	(64)
<b>Glioblastoma multiforme</b>	25%	5%	28-8	(38)
	45%	50%	NR	(85)
<b>Breast cancer</b>	18% TNBC (0% ER/PR/HER2+)	5%	28-8	(38)
	43% overall (59% TNBC)	NR	R&D B7-H1	(37)
	50%	1%	MIH1	(86)
<b>Gastric</b>	42%	NR	2H11	(87)
<b>Esophageal</b>	20%	5%	28-8	(38)
	44% (squamous)	10%	MIH1	(88)
<b>Hepatocellular carcinoma</b>	15%	5%	28-8	(38)
	25%	NR	eBioscience anti-B7-H1	(89)
<b>Pancreatic</b>	39%	10%	MIH1	(90)
<b>Colorectal</b>	53%	>10%	5H1	(24)
	56% (MSI-H) vs. 21% (MSS)	NR	Caris	(42)
<b>Thymic cancer</b>	100% (thymoma), 88% (thymic carcinoma)	NR	29E (.5A9/.2A3)	(91)
	100% (thymoma and thymic carcinoma)	NR	Sino clone 15	(92)
<b>Ovarian</b>	87%	>10%	5H1	(24)
	89%	5%	27A2	(20)
<b>Sarcoma</b>	12% (27% GIST)	1%	DAKO PD-L1 IHC	(28)
<b>Unknown Primary</b>	28%	5%	28-8	(38)
<b>Acute Myeloid Leukemia</b>	37%	5%	MIH1	(93)
<b>Leukemias (various)</b>	57%	NR	5H1	(94)
<b>B cell Lymphomas</b>	58%	5%	DFCI 339.7G11	(27)
<b>Multiple Myeloma</b>	93%	NR	N20 antihuman PD-L1	(59)

Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; H-score, immunoreactivity score: (3 x percentage of strongly staining tumor cells) + (2 x percentage of moderately staining tumor cells) + (percentage of weakly staining tumor cells), range of 0 to 300;

IHC, immunohistochemistry; MSI-H, microsatellite instability-high; MSS, microsatellite stable; NR, not reported; PR, progesterone receptor; TNBC, triple negative breast cancer

**Table 2.**  
**Examples of available PD-L1 detection and therapeutic antibodies**

Therapeutic agent	Company	Companion PD-L1 detection antibody	Examples of trials by histology	Comments
<b>Anti-PD-1</b>				
<b>Nivolumab</b>	BMS	28-8	Melanoma, NSCLC, RCC, Hodgkin's lymphoma, other solid tumors	FDA (USA) approved for refractory unresectable/advanced melanoma (12/22/14). Approved in Japan for unresectable melanoma (7/4/14)
<b>Pembrolizumab (MK-3475, Lambrolizumab)</b>	Merck	Merck PD-L1 IHC assay	NSCLC, other solid tumors	FDA (USA) approved for ipilimumab-refractory melanoma (9/4/14)
<b>Pidilizumab (CT-011)</b>	Curetech		NHL, Melanoma, RCC	
<b>AMP-224, AMP-514</b>	Amplimmune		Phase 1	
<b>"Anti-PD-1"</b>	Novartis/CoStim		Phase 1	
<b>Anti-PD-L1</b>				
<b>BMS-946559</b>	BMS	28-8		
<b>MPDL3280A</b>	Genentech/Roche	Roche PD-L1 IHC assay	NSCLC, melanoma, RCC	
<b>MEDI4736</b>	MedImmune/Astrazeneca	SP263 Ventana IHC	NSCLC, other solid tumors	
<b>MSB0010718C</b>	EMD Serono (Merck)		Phase 1	

Abbreviations: BMS, Bristol-Myers Squibb; IHC, immunohistochemistry; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma

Table 3

Comparison of overall response rates to anti-PD-1 and anti-PD-L1 therapy based on histology and PD-L1 IHC expression

Therapeutic agent	Detection antibody; membrane staining cutoff (in percent of tumor cells)	Histology	PD-L1 IHC expression (% samples at IHC level)	Response rate for PD-L1 positive versus PD-L1 negative patients	PFS for PD-L1 positive versus PD-L1 negative patients	OS for PD-L1 positive versus PD-L1 negative patients	Ref(s)
Nivolumab	28-8; 5%	Melanoma (n=38)	+ (45%) - (55%)	44% vs. 17% (p=NR)	9.1 vs. 2 months (median PFS, p= NR)	21.1 vs. 12.5 months (median OS, p=NR)	(76)
	DAKO; 5%	NSCLC (n=20)	+ (60%) - (40%)	67% vs. 0% (p=NR)	NR	NR	(71)
	5H1; 5%	Melanoma, RCC, NSCLC, CRC, prostate	+ (60%) - (40%)	36% vs. 0% (p=NR)	NR	NR	(4)
Pembrolizumab	NR; 1%	Melanoma (n=71)	+ (77%) - (23%)	51% vs. 6% (p=0.0012)	12 vs. 3 months (median PFS; p=0.0004)	84% vs. 69% (1- year OS rate; p=0.2146)	(70)
	NR; 50%	NSCLC (n=38)	+ (25%) - (75%)	67% vs. 0% (6- month irORR; p<0.001)	67% vs. 11% (6- month PFS rate; p=0.009)	89% vs. 33% (6- month OS rate; p=NR)	(49)
MPDL3280A	Roche/Genentech	NSCLC, RCC, melanoma, CRC, gastric cancer	NR	39% vs. 13% (p=NR)	NR	NR	(26),(73)
	Roche/Genentech	NSCLC (n=37)	+ (13%) - (87%)	100% vs. 15% (p=NR)	NR	NR	(72)
	Roche/Genentech	Bladder (n= 20)	NR	52% vs. 11% (p=NR)	NR	NR	(25)

Abbreviations:

CRC, colorectal cancer; IHC, immunohistochemistry; irORR, immune-related overall response rate; NR, not reported; NSCLC, non-small cell lung cancer; PFS, progression-free survival; OS, overall survival; RCC, renal cell carcinoma




Table 4.

PD-L1 expression in primary vs. metastasis

Tumor Histology	Detection Antibody	Primary Lesion (% tumor cells positive for PD-L1)	Metastatic Lesion (% tumor cells positive for PD-L1)	Comment	Ref(s)
Renal Cell Carcinoma	5H1	44%	43%	Unmatched (different patient) primary and metastatic samples	(77)
	405.9A11	30%	27%	Matched (same patient) primary and metastatic samples	(66)
Melanoma	5H1	35%	43%	Unmatched (different patient) primary and metastatic samples	(54)
Triple-negative breast cancer	NR	100%	92%	Matched (same patient) primary and metastatic samples	(95)

Abbreviations: H-score, immunoreactivity score: (3 x percentage of strongly staining tumor cells) + (2 x percentage of moderately staining tumor cells) + (percentage of weakly staining tumor cells), range of 0 to 300; NR, not reported



# PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Sandip Pravin Patel and Razelle Kurzrock

*Mol Cancer Ther* Published OnlineFirst February 18, 2015.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1535-7163.MCT-14-0983](https://doi.org/10.1158/1535-7163.MCT-14-0983)

**Author Manuscript** Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, contact the AACR Publications Department at [permissions@aacr.org](mailto:permissions@aacr.org).